Yun-Hee Choi1, Lajmi Lakhal-Chaieb2, Agnieszka Kröl3, Bing Yu1, Daniel Buchanan4, Dennis Ahnen5, Loic Le Marchand6, Polly A Newcomb7, Aung Ko Win4, Mark Jenkins4, Noralane M Lindor8, Laurent Briollais3,9. 1. Department of Epidemiology and Biostatistics, Western University, London, ON, Canada. 2. Department of Mathematics and Statistics, Laval University, Québec, QC, Canada. 3. Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. 4. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia. 5. Division of Gastroenterology, Faculty of Medicine, University of Colorado, Aurora, CO. 6. Population Sciences in the Pacific Program (Cancer Epidemiology), University of Hawaii Cancer Center, Honolulu, HI. 7. Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA. 8. Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ. 9. Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND: The risk of cancers is well characterized in Lynch syndrome (LS) families but has been less studied in familial colorectal cancer type X (FCCTX) families. METHODS: In this article, we compare the risk estimates of first and second colorectal cancers (CRCs) in 168 FCTTX and 780 LS families recruited through the Colon Cancer Family Registry as well as the risk of cancer-related deaths and disease-free survival (DFS) after a first CRC. Our methodology is based on a survival analysis approach, developed specifically to model the occurrence of successive cancers (ie, first and second CRCs) in the presence of competing risk events (ie, death from any causes). RESULTS: We found an excess risk of first and second CRC in individuals with LS compared to FCCTX family members. However, for an average age at first CRC of 60 years in FCCTX families and 50 years in LS families, the DFS rates were comparable in men but lower in women from FCCTX vs LS families, eg , 75.1% (95% confidence interval [CI] = 69.0% to 80.9%) vs 78.9% (95% CI = 76.3% to 81.3%) for the 10-year DFS. The 10-year risk of cancer-related death was higher in FCCTX families vs LS families, eg, 15.4% in men (95% CI = 10.9% to 19.8%) and 19.3% in women (95% CI = 13.6% to 24.7%) vs 8.9% (95% CI = 7.5% to 11.4%) and 8.7% (95% CI = 7.1% to 10.8%), respectively. CONCLUSIONS: Individuals with CRCs arising in the context of FCCTX do not experience the same improved DFS and overall survival of those with LS, and that difference may be relevant in management decisions.
BACKGROUND: The risk of cancers is well characterized in Lynch syndrome (LS) families but has been less studied in familial colorectal cancer type X (FCCTX) families. METHODS: In this article, we compare the risk estimates of first and second colorectal cancers (CRCs) in 168 FCTTX and 780 LS families recruited through the Colon Cancer Family Registry as well as the risk of cancer-related deaths and disease-free survival (DFS) after a first CRC. Our methodology is based on a survival analysis approach, developed specifically to model the occurrence of successive cancers (ie, first and second CRCs) in the presence of competing risk events (ie, death from any causes). RESULTS: We found an excess risk of first and second CRC in individuals with LS compared to FCCTX family members. However, for an average age at first CRC of 60 years in FCCTX families and 50 years in LS families, the DFS rates were comparable in men but lower in women from FCCTX vs LS families, eg , 75.1% (95% confidence interval [CI] = 69.0% to 80.9%) vs 78.9% (95% CI = 76.3% to 81.3%) for the 10-year DFS. The 10-year risk of cancer-related death was higher in FCCTX families vs LS families, eg, 15.4% in men (95% CI = 10.9% to 19.8%) and 19.3% in women (95% CI = 13.6% to 24.7%) vs 8.9% (95% CI = 7.5% to 11.4%) and 8.7% (95% CI = 7.1% to 10.8%), respectively. CONCLUSIONS: Individuals with CRCs arising in the context of FCCTX do not experience the same improved DFS and overall survival of those with LS, and that difference may be relevant in management decisions.
Authors: Karolin Bucksch; Silke Zachariae; Stefan Aretz; Reinhard Büttner; Elke Holinski-Feder; Stefanie Holzapfel; Robert Hüneburg; Matthias Kloor; Magnus von Knebel Doeberitz; Monika Morak; Gabriela Möslein; Jacob Nattermann; Claudia Perne; Nils Rahner; Wolff Schmiegel; Karsten Schulmann; Verena Steinke-Lange; Christian P Strassburg; Deepak B Vangala; Jürgen Weitz; Markus Loeffler; Christoph Engel Journal: BMC Cancer Date: 2020-05-24 Impact factor: 4.430
Authors: Christina Therkildsen; Maria Rasmussen; Lars Smith-Hansen; Thomas Kallemose; Lars Joachim Lindberg; Mef Nilbert Journal: BMC Cancer Date: 2020-04-22 Impact factor: 4.430
Authors: Felipe Antonio de Oliveira Garcia; Edilene Santos de Andrade; Henrique de Campos Reis Galvão; Cristina da Silva Sábato; Natália Campacci; Andre Escremin de Paula; Adriane Feijó Evangelista; Iara Viana Vidigal Santana; Matias Eliseo Melendez; Rui Manuel Reis; Edenir Inez Palmero Journal: Sci Rep Date: 2022-02-18 Impact factor: 4.379